Loading
institutionsInstitution
Stand Up To Cancer
An entertainment-industry charity that funds multi-institution Dream Teams, with AACR as scientific partner, to move discoveries into trials quickly.
Also called: SU2C
Overview
Founded in 2008 by film and television leaders, Stand Up To Cancer raises money through televised specials and channels it through the American Association for Cancer Research, its scientific partner, into Dream Teams that bring institutions together around a single translational goal with milestone-based funding. Dream Teams have covered prostate cancer (with the Prostate Cancer Foundation), pancreatic cancer (with the Lustgarten Foundation), lung cancer, paediatric cancer, immunotherapy and early detection, and SU2C also funds Innovative Research Grants and a Health Equity Initiative to diversify trial enrolment. Stand Up To Cancer Canada and UK partnerships extend the model.
Location
Los Angeles, US
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#389 · 16 points (0 Newsweek + 0 NCI + 16 from 8 linked objects) · ranking
- Dream Teams (prostate, pancreatic, lung, paediatric, immunotherapy)
- Innovative Research Grants
- Health Equity Initiative
- Televised fundraising
Julian Adams
President and CEO
Drug discoveryProteasome inhibitorsMultiple myeloma
Medicinal chemist who led the discovery of the proteasome inhibitor bortezomib and now heads Stand Up To Cancer as President and CEO.
Sherry Lansing
Film executive who co-founded Stand Up To Cancer in 2008
Cancer research fundraisingTeam scienceEntertainment philanthropy
The former Paramount chief co-founded Stand Up To Cancer, whose televised specials and Dream Teams have pledged over $800 million to collaborative research that fed into several approved cancer drugs.
William G. Nelson
Director, Sidney Kimmel Comprehensive Cancer Center
Prostate cancerEpigeneticsCancer prevention
William Nelson is the long-time director of the Johns Hopkins cancer centre and a prostate cancer epigenetics researcher.
Charles L. Sawyers
Chair, Human Oncology and Pathogenesis Program; HHMI Investigator
Prostate cancerKinase inhibitor resistanceAndrogen receptor biology
Co-developed imatinib's successor dasatinib and the prostate drug enzalutamide, and explained how cancers resist targeted drugs.
David A. Tuveson
Director, CSHL Cancer Center; Roy J. Zuckerberg Professor
Pancreatic cancerOrganoidsTumour stroma
Built the pancreatic cancer organoid models now used to test drugs against a patient's own tumour.
Howard I. Scher
Member, Genitourinary Oncology Service; Head, Biomarker Development Program
Prostate cancerCirculating tumour cellsAR-V7
Defined how prostate cancer trials are run and read, from PSA working-group criteria to circulating tumour cell biomarkers.
Similar pages
- InstitutionProstate Cancer Foundation
Shares Prostate Cancer Foundation (PCF), Charles L. Sawyers, The valley of death between lab and product, Prostate cancer.
- InstitutionEuropean Association for Cancer Research
Shares American Association for Cancer Research (AACR), The valley of death between lab and product, Cancer Research UK.
- PersonMichael Milken
Shares Charles L. Sawyers, The valley of death between lab and product, Prostate cancer.
- InstitutionThe Mark Foundation for Cancer Research
Shares American Association for Cancer Research (AACR), The valley of death between lab and product, Cancer Research UK.
- PersonLinda Tantawi
Shares Lustgarten Foundation, Pancreatic ductal adenocarcinoma.
- IdeaFund investigators from under-represented communities and community sites to lead trials
Shares American Association for Cancer Research (AACR), Trials do not represent the people who get cancer.
- Key paperInhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
- IdeaDedicated cohorts for patients with performance status 2 in first-line trials
Shares Trials do not represent the people who get cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.